Ellen Sinclair Webber, MD
Family Medicine · Ottawa, KSNPI 1861429458
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $843, more than ten times the $78 reported in 2019.
Across 207 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$572
- Lilly USA, LLC$475
- Amgen$433
- AstraZeneca$355
- AbbVie$254
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$157
- plus $1K from 33 others
What the payments were for
- Food & beverage$3,413100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $572 |
| Lilly USA, LLC | 28 | $475 |
| Amgen | 29 | $433 |
| AstraZeneca(2 entities) | 21 | $355 |
| AbbVie | 12 | $254 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $157 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $118 |
| Kowa Pharmaceuticals America, Inc. | 6 | $77 |
| Johnson & Johnson | 5 | $69 |
| Sanofi Pasteur Inc. | 4 | $68 |
| Merck | 4 | $66 |
| Astellas Pharma US Inc | 4 | $63 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Biohaven Pharmaceuticals, Inc. | 4 | $59 |
| Sunovion Pharmaceuticals Inc. | 3 | $54 |
| Boehringer Ingelheim | 3 | $48 |
| Idorsia Pharmaceuticals US Inc | 2 | $40 |
| Biogen | 2 | $38 |
| Sanofi | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Lundbeck LLC | 2 | $31 |
| GSK | 2 | $28 |
| MML US, Inc. | 1 | $25 |
| GRT US Holding, Inc. | 1 | $22 |
| Abbott | 1 | $21 |
| Seqirus USA Inc | 1 | $21 |
| Novartis | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Saluda Medical Americas, Inc. | 1 | $19 |
| Krystal Biotech Inc | 1 | $19 |
| Pfizer | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Bayer | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $9 |
| Endogastric Solutions, Inc | 2 | $8 |
How this compares
$3,422 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TradjentaLinagliptin | 33 | $23,744 |
| EliquisApixaban | 20 | $17,992 |
| OzempicSemaglutide | 14 | $10,702 |
| TrulicityDulaglutide | 11 | $10,576 |
| Duloxetine Hcl | 147 | $2,022 |
| Potassium Chloride | 58 | $1,820 |
| Levothyroxine Sodium | 292 | $1,705 |
| Rosuvastatin Calcium | 136 | $1,697 |
| Losartan Potassium | 209 | $1,598 |
| Pravastatin Sodium | 110 | $1,305 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 75 | $1,182 |
| Lansoprazole | 51 | $1,157 |
| Atorvastatin Calcium | 143 | $909 |
| Pantoprazole Sodium | 114 | $847 |
| Fenofibrate | 46 | $765 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta | $48 | $23,74433 claims |
| PfizerEliquis | $18 | $17,99220 claims |
| Novo NordiskOzempic | $572 | $10,70214 claims |
| Lilly USA, LLCTrulicity | $475 | $10,57611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Ottawa
- John GollierOttawa$11K
- Bradley HarrisonManhattan$314K
- Mila MeansWichita$241K
- Scott AveryJunction City$195K
- Kent KiracofeManhattan$189K
- Terry McGeeneyLeawood$147K
- Cole GillenwaterWichita$62K
- David StricklandLawrence$53K
- Kyle PlatzManhattan$51K
- Eric AspinwallKansas City$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.